Kidney Cancer Coverage from Every Angle

Is Monosomy of Chromosome 9 Linked to Adverse Outcomes in Renal Cell Carcinoma?

By: Cordi Craig
Posted: Thursday, March 26, 2020

A study published in Clinical Genitourinary Cancer reported that almost one-third of patients with clear cell renal cell carcinoma who underwent surgery were in part or entirely missing chromosome 9. The loss of chromosome 9, or monosomy 9, was associated with adverse disease characteristics, including higher histologic grade, more advanced-stage disease, and shorter recurrence-free survival than those with chromosome 9.

“Since chromosome 9 contains many important tumor-suppressor genes, such as CDKN2A and PTCH1, on the short arm and long arm of chromosome 9, respectively, we were interested in looking at this chromosome in these patients,” Reza Nejati, MD, of the Fox Chase Cancer Center, Philadelphia, stated in a Fox Chase press release.

Using single-nucleotide polymorphism-based chromosome microarray analysis, the researchers examined 103 samples of clear cell renal cell carcinoma. All patients underwent partial or radical nephrectomy.

The research team detected the loss of chromosome 9 in 31 samples (30%). Tumors with the abnormal chromosome 9 loss were correlated with higher histologic grade (P < .001) and pathologic stage (P < .001). Among patients with nonmetastatic renal cell carcinoma (n = 59), monosomy 9 was related to a higher disease recurrence rate and shorter recurrence-free survival (P = .002).

“Advanced imaging technologies have meant that more of these cancers are being diagnosed in earlier stages,” Dr. Nejati continued. “Because of that, it would be very useful for clinicians to know which patients have a higher risk and should be treated more aggressively, and which patients can be offered less aggressive treatments.”

Disclosure: For disclosures of the study authors, visit

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.